- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01694108
Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.
Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. A Prospective, Randomised, Clinical Trial.
In high-income societies the use of health care and medication is steadily increasing. Children have high morbidity, many visits at the general practitioner, an increasing number of hospitalisations, and an increasing use of medication. And, when children are ill, someone has to stay home to care for them. An un-explained global increase in the incidence of the allergic diseases eczema, wheezing, asthma and allergies means that 25% of high-income populations are affected. Cheap preventive measures are highly warranted. Recent studies have shown a positive, non-specific effect of early Bacille Calmette Guérin (BCG) immunisation on neonatal mortality in low-income countries and suggested a positive, non-specific effect on allergic disease in high-income countries. "Non-specific" means that the vaccine effect goes beyond prevention of the targeted disease, i.e. the BCG vaccine benefits the health status of the immunised individual in ways unrelated to protection against tuberculosis (TB). For instance, in a recent randomised trial in West Africa the investigators showed that the BCG vaccine at birth was safe in low birth weight (LBW) infants and significantly reduced neonatal mortality in these children, with a significant long-lasting effect on infant mortality in the smallest newborns with a birth weight <1.5 kg. There is an urgent need to explore the huge potential of the BCG's beneficial immune-stimulatory effects among children in high-income populations.
Therefore, the investigators will carry out a large prospective randomised clinical trial in Denmark primarily designed to test the hypothesis that infants who get the BCG vaccine at birth experience 20% fewer hospitalisations during early childhood.
Secondary outcomes
- To test the hypothesis that infants who get the BCG vaccine at birth are prescribed less antibiotics during early childhood than non-BCG-immunised infants.
- To test the hypothesis that Danish infants who get the BCG vaccine at birth develop less eczema, asthmatic bronchitis/wheeze and food allergy at 3 and 12 months of age: self-reported, diagnosed by a physician, or found at clinical examination; and are prescribed less anti-eczema/asthma/allergy medication during early childhood than non-BCG-immunised infants.
- To test the hypothesis that infants who receive the BCG at birth respond in paraclinical measures: Specific IgE, thymic gland size, leucocyte count and differentiation, monocyte memory, cytokine profiles, and antibody titres following immunisation against diphtheria, tetanus, pertussis, pneumococcus, hemophilus.
- To test the hypothesis that infants who get the BCG vaccine at birth respond in growth measures: weight, length and head circumference.
- To test the hypothesis that infants who get the BCG vaccine at birth respond with decreased morbidity: common cold, pneumonia, febrile episodes, diarrhoea and vomiting, acute otitis media, febrile convulsions.
- To test the hypothesis that premature infants with gestational age less than 37 weeks who get the BCG vaccine at birth have unaffected psychomotor development measures: Ages and Stages scores.
- To test the hypothesis that infants who get the BCG vaccine at birth has unaffected coverage with the subsequent vaccinations in the Child Vaccination Programme.
- To test the above mentioned hypotheses specifically in the strata of premature and low-birth-weight Danish infants.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2650
- Hvidovre Hospital
-
Kolding, Denmark, 6000
- Kolding Sygehus
-
-
Copenhagen Ø
-
Copenhagen, Copenhagen Ø, Denmark, 2100
- Rigshospitalet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All parents planning to give birth at Rigshospitalet, Hvidovre Hospital and Kolding Hospital will receive at letter during 2nd/3rd trimester of pregnancy with information on the study and be offered inclusion in the study.
Exclusion Criteria:
- Infants born before gestational age 32 weeks and/or birth weight < 1000g, infants with known congenital disease, anomaly or malformation, immune deficiency and HIV, will be excluded. Non-Danish speaking parents will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BCG-vaccine (SSI)
Children born to mothers, who have accepted to participate, will be randomised to either intervention group or to the control group at birth. Block-randomisation stratified by hospital, gender and gestational age (≥37 weeks of gestation vs. < 37 weeks of gestation) will be performed electronically just before vaccination by the overall study electronic case report system (e-crf). Children randomised to the BCG vaccination group will receive an intradermal BCG vaccine (Statens Serum Institute "CG vaccine" in the standard dose 0.05 ml in the upper, lateral part of the arm of the child by a specially trained midwife or a study physician. |
|
No Intervention: No Intervention
Control children will be treated as usual, since no suitable placebo exists.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause Hospitalisations
Time Frame: 0-15 months of age
|
To test that infants who get the BCG vaccine at birth experience 20% fewer hospitalisations in early childhood than non-BCG-immunised infants.
|
0-15 months of age
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antibiotics
Time Frame: 0-15 months of age
|
To test that infants who get the BCG vaccine at birth are prescribed less antibiotics during early childhood than non-BCG-immunised infants.
Use of antibiotics was defined as one or more precriptions of systemic antibiotics (ATC groups J01, J02, J05, all subgroups inclusive).
|
0-15 months of age
|
Atopic Dermatitis
Time Frame: 13 months of age
|
To test if BCG vaccination within 7 days after birth influence the risk of atopic dermatitis defined by clinical examination at 13 months of age using "scoring atopic dermatitis (SCORAD)" or by parental report of physician diagnosed atopic dermatitis in the telephone interview at 13 months of age.
|
13 months of age
|
Specific IgE
Time Frame: 13 months of age
|
Number of participants with specific IgE (Phadiatop Infant) above the clinical cut-of level of 0.35.
|
13 months of age
|
Standardized Weight at 13 Months
Time Frame: 13 months of age
|
To test that infants who get the BCG vaccine at birth respond in weight.The Z-score indicates the number of standard deviations away from the mean weight-for-age of the WHO anthropometric reference population (http://www.who.int/childgrowth/standards/en/).
A Z-score of 0 is equal to the mean.
Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.
|
13 months of age
|
Psychomotor Development in Premature Infants
Time Frame: 13 months of age
|
To test that premature infants with gestational age less than 37 weeks who get the BCG vaccine at birth have unaffected psychomotor development measures: ASQ: Ages and stages questionnaire - a parent reported questionnaire that measures child psychomotor development.
Total range of ASQ score: 0 to 300 points.
Higher scores indicate higher level of psychomotor development.
|
13 months of age
|
DTaP-IPV-Hib Vaccination Coverage at 12 Months of Age
Time Frame: 13 months of age
|
To test that infants who get the BCG vaccine at birth has unaffected coverage with the subsequent 3rd diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type b (DTaP-IPV-Hib) vaccination scheduled to 12 months of age according to the Danish child vaccination programme.
Since we did not expect all children to get their immunizations exactly at 12 months of age, the children were followed up until 13-months of age.
|
13 months of age
|
Standardized Weight, Length and Head Circumference of Premature Children at 13 Months
Time Frame: 13 months of age
|
The Z-score indicates the number of standard deviations away from the mean weight-for-age of the WHO anthropometric reference population (http://www.who.int/childgrowth/standards/en/).
A Z-score of 0 is equal to the mean.
Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.
|
13 months of age
|
Episodic Viral Wheeze
Time Frame: 13 months
|
Number of participants diagnosed with episodic viral wheeze by a physician and treated with anti-asthmatic medicine according to the telephone interview.
|
13 months
|
Food Allergy
Time Frame: 13 months
|
Number of participants with food allergy diagnosed by a physician and mentioned in the telephone interview at 13 months of age
|
13 months
|
Length at 13 Months of Age
Time Frame: 13months
|
To test if infants who get the BCG vaccine at birth respond in length.
The Z-score indicates the number of standard deviations away from the mean weight-for-age of the WHO anthropometric reference population (http://www.who.int/childgrowth/standards/en/).
A Z-score of 0 is equal to the mean.
Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.
|
13months
|
Standardized Head Circumference at 13 Months of Age
Time Frame: 13 months
|
To test if infants who get the BCG vaccine at birth respond in head circumference.
The Z-score indicates the number of standard deviations away from the mean weight-for-age of the WHO anthropometric reference population (http://www.who.int/childgrowth/standards/en/).
A Z-score of 0 is equal to the mean.
Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.
|
13 months
|
Thymic Gland Size at 3 Months of Age
Time Frame: 3 months of age
|
To test that infants who receive the BCG at birth respond in thymic gland size defined by ultra sound examination.
First, the thymus gland was identified in a horizontal scanning plane and the largest transverse diameter of the thymus was obtained.
Second, in a sagittal scanning plane, the area of the largest lobe was assessed.
Both measurements were obtained twice, and in case of more than 15% difference, both measurements were repeated.
The mean of the two measurements were multiplied and defined as the thymic index.
|
3 months of age
|
Leucocyte Count 4 Days After Randomisation/Vaccination
Time Frame: 4 days after randomisation/vaccination within 7 days after birth
|
To test if infants who receive the BCG at birth respond in leucocyte count (white blood cell count) measured as geometric mean (GM) cell concentrations (GM*10^9 cells/L).
|
4 days after randomisation/vaccination within 7 days after birth
|
Monocyte Count 4 Days After Randomisation/Vaccination
Time Frame: 4 days after randomisation/vaccination within 7 days after birth
|
To test if infants who receive the BCG at birth respond in monocyte count measured as geometric mean (GM) cell concentrations (GM*10^9 cells/L).
|
4 days after randomisation/vaccination within 7 days after birth
|
Interferon Gamma Response
Time Frame: 13 months of age
|
To test that infants who receive the BCG at birth respond in interferon-gamma response upon stimulation with BCG.
The interferon gamma response was defined as a value above the cut-off value of 107 pg/ml.
|
13 months of age
|
Number of Participants With Antibody Concentration (AC) Against Tetanus of > 0.1 IU/mL
Time Frame: 13 months of age
|
To test the tetenus antibody response in BCG-vaccinated vs. non-BCG vaccinated children following routine immunisation against tetanus at 3, 5 and 12 months of age in blood samples obtained 13 months of age.
|
13 months of age
|
Number of Events of Common Cold
Time Frame: 13 months of age
|
To test that Danish infants who get the BCG vaccine at birth experience less events of common cold until 13 months of age than non-BCG-immunised infants.
|
13 months of age
|
Number of Events of Pneumonia
Time Frame: 13 months of age
|
To test that Danish infants who get the BCG vaccine at birth get less pneumonia at 13 months of age than non-BCG-immunised infants.
|
13 months of age
|
Number of Events of Febrile Episodes
Time Frame: 13 months of age
|
To test that Danish infants who get the BCG vaccine at birth get less febrile episodes at 13 months of age than non-BCG-immunised infants.
|
13 months of age
|
Number of Events With Diarrhoea and Vomiting
Time Frame: 13 months of age
|
To test that Danish infants who get the BCG vaccine at birth develop less episodes with diarrhoea and vomiting at 13 months of age than non-BCG-immunised infants.
|
13 months of age
|
Number of Events of Acute Otitis Media
Time Frame: 13 months of age
|
To test that Danish infants who get the BCG vaccine at birth develop less acute otitis media at 13 months of age than non-BCG-immunised infants.
|
13 months of age
|
Number of Events of Febrile Convulsions
Time Frame: 13 months of age
|
To test that Danish infants who get the BCG vaccine at birth develop less febrile convulsions at 13 months of age than non-BCG-immunised infants.
|
13 months of age
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decisional Conflict Scale Score
Time Frame: The decisional conflict score was measured before randomisation
|
After parents having made the decision about whether to accept vaccination of their newborn through participation in The Danish Calmette Study, O'Connor's Decisional Conflict Scale was used to identify decisional conflicts.
The score ranges from 0 (no decisional conflict) til 100 (maximum decisional conflict).
Scores lower than 25 are associated with implementing decisions; scores exceeding 37.5 are associated with decision delay or feeling unsure about implementation; so a low score reflects a low level of doubt about the decision about participation/decline participation in the trial, and a high score reflects a high level of doubt.
|
The decisional conflict score was measured before randomisation
|
Quality of Communication and Information
Time Frame: 2 days after the information was given
|
To test that the use of telephone and internet was acceptable in the study population using the Quality of Informed Consent (QuIC) questionnaire.
The questionnaire was divided into six categories; five on study comprehension and one on satisfaction with the information process.
The items in the first five categories could be answered with "yes", "no" or "do not know".
The last category was rated on a 7-point Likert scale, with 1 being "very dissatisfied" and 7 being "very satisfied".
The primary outcome was the sum of the score for comprehension items and satisfaction items.
Comprehension items were scored 1 point for each correct answer and 0 points for each incorrect answer.
Satisfaction items were scored as rated on the 7-point Likert scale.
Total score ranged from 7 to 69 points, comprehension score from 0 to 20 points and satisfaction score from 7 to 49 points.
The higher score, the better comprehension and satisfaction.
|
2 days after the information was given
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lone G Stensballe, MD, PhD, Rigshospitalet. The Danish National Hospital in Denmark.
Publications and helpful links
General Publications
- Birk NM, Nissen TN, Ladekarl M, Zingmark V, Kjaergaard J, Jensen TM, Jensen SK, Thostesen LM, Kofoed PE, Stensballe LG, Andersen A, Pryds O, Nielsen SD, Benn CS, Jeppesen DL. The association between Bacillus Calmette-Guerin vaccination (1331 SSI) skin reaction and subsequent scar development in infants. BMC Infect Dis. 2017 Aug 3;17(1):540. doi: 10.1186/s12879-017-2641-0.
- Kjaergaard J, Birk NM, Nissen TN, Thostesen LM, Pihl GT, Benn CS, Jeppesen DL, Pryds O, Kofoed PE, Aaby P, Greisen G, Stensballe LG. Nonspecific effect of BCG vaccination at birth on early childhood infections: a randomized, clinical multicenter trial. Pediatr Res. 2016 Nov;80(5):681-685. doi: 10.1038/pr.2016.142. Epub 2016 Jul 18.
- Stensballe LG, Sorup S, Aaby P, Benn CS, Greisen G, Jeppesen DL, Birk NM, Kjaergaard J, Nissen TN, Pihl GT, Thostesen LM, Kofoed PE, Pryds O, Ravn H. BCG vaccination at birth and early childhood hospitalisation: a randomised clinical multicentre trial. Arch Dis Child. 2017 Mar;102(3):224-231. doi: 10.1136/archdischild-2016-310760. Epub 2016 Jul 21.
- Kjaergaard J, Stensballe LG, Birk NM, Nissen TN, Thostesen LM, Pihl GT, Nielsen AV, Kofoed PE, Aaby P, Pryds O, Greisen G. Bacillus Calmette-Guerin vaccination at birth: Effects on infant growth. A randomized clinical trial. Early Hum Dev. 2016 Sep;100:49-54. doi: 10.1016/j.earlhumdev.2016.05.015. Epub 2016 Jul 7.
- Kjaergaard J, Stensballe LG, Birk NM, Nissen TN, Foss KT, Thostesen LM, Pihl GT, Andersen A, Kofoed PE, Pryds O, Greisen G. Lack of a Negative Effect of BCG-Vaccination on Child Psychomotor Development: Results from the Danish Calmette Study - A Randomised Clinical Trial. PLoS One. 2016 Apr 28;11(4):e0154541. doi: 10.1371/journal.pone.0154541. eCollection 2016.
- Nissen TN, Birk NM, Kjaergaard J, Thostesen LM, Pihl GT, Hoffmann T, Jeppesen DL, Kofoed PE, Greisen G, Benn CS, Aaby P, Pryds O, Stensballe LG. Adverse reactions to the Bacillus Calmette-Guerin (BCG) vaccine in new-born infants-an evaluation of the Danish strain 1331 SSI in a randomized clinical trial. Vaccine. 2016 May 11;34(22):2477-82. doi: 10.1016/j.vaccine.2016.03.100. Epub 2016 Apr 7.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EudraCT2010-021979-85
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prospective
-
Sahlgrenska University Hospital, SwedenStryker NordicRecruiting
-
Wuhan Union Hospital, ChinaRenmin Hospital of Wuhan University; Beijing Tsinghua Changgeng HospitalCompleted
-
University Hospital, BrestRecruitingProspective StudyFrance
-
National Institute of Allergy and Infectious Diseases...Bristol-Myers Squibb; PPD; Rho Federal Systems Division, Inc.; Immune Tolerance...RecruitingHighly Sensitized Prospective Kidney Transplant RecipientsUnited States
-
National Institute of Allergy and Infectious Diseases...Bristol-Myers Squibb; PPD; Rho Federal Systems Division, Inc.; Immune Tolerance...RecruitingHighly Sensitized Prospective Kidney Transplant RecipientsUnited States
-
Alejandro Reyes SánchezCompletedRandomized Controlled Trial | Prospective Study | Tranexamic Acid (TXA) | Evidence-based MedicineMexico
-
Singapore General HospitalUnknown
-
Joacim StalforsKarolinska Institutet; Linkoeping University; Sahlgrenska University Hospital... and other collaboratorsUnknownPostoperative Complications | Tonsillectomy | Prospective Studies | RegistriesSweden
-
Renmin Hospital of Wuhan UniversityRecruitingInterventional | Prospective | Self ControlChina
-
University of Southern CaliforniaCompletedProspective | Carbon Dioxide | Angiogram | Endovascular Abdominal Aortic Aneurym RepairUnited States
Clinical Trials on BCG-vaccine (SSI)
-
Radboud University Medical CenterCompletedInnate Immune Response
-
Radboud University Medical CenterCompleted
-
AerasSanofi Pasteur, a Sanofi CompanyCompleted
-
University of OxfordUniversity of Birmingham; AerasCompleted
-
Bill & Melinda Gates Medical Research InstituteActive, not recruiting
-
Mark HatherillMedical Research Council; University of Oxford; Wellcome Trust; Department for... and other collaboratorsCompletedSafety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination (MVA(TB)029)HIV | TuberculosisSouth Africa
-
Radboud University Medical CenterUniversity of Southern DenmarkUnknown
-
Bandim Health ProjectUniversity of Southern DenmarkRecruitingMorbidity;Newborn | Non-specific Effects of Vaccines | Death, Infant | Morbidity;Infant | Death; NeonatalGuinea-Bissau
-
Bandim Health ProjectOdense University Hospital; Odense Patient Data Explorative Network; Municipality...CompletedCovid19 | Immunosenescence | Vaccine Preventable Disease | Morbidity | Non-specific Effects of Vaccines | Heterologous ImmunityDenmark
-
Radboud University Medical CenterRecruitingEpigenetics | Trained Immunity | BCG VaccineNetherlands